
Sign up to save your podcasts
Or


Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.
By Down Round4.8
99 ratings
Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.

1,986 Listeners

8,855 Listeners

273 Listeners

590 Listeners

267 Listeners

580 Listeners

285 Listeners

965 Listeners

314 Listeners

594 Listeners

12 Listeners

16 Listeners

301 Listeners

204 Listeners

109 Listeners